Amgen study demonstrates cognitive safety of cholesterol drug Repatha

Amgen has announced the findings of a new study that further underlines the strong safety performance of its cholesterol therapy Repatha.

Data published in the New England Journal of Medicine from the Repatha cognitive function trial showed that Repatha was non-inferior to placebo in terms of its lack of impairment of cognitive function.

Repatha was shown to have no notable negative impact on any of the cognitive domains tested, including executive function, working memory, memory function and psychomotor speed.

This is a noteworthy discovery, as the clinical cardiology community has harboured historical concerns that low levels of low-density lipoprotein (LDL) cholesterol may impact cognitive function.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "These findings add to the body of evidence supporting the safety of LDL-lowering with Repatha in patients with established cardiovascular disease who need more than statin therapy alone."

Repatha is approved in more than 50 countries, including the US, Japan, Canada and all 28 countries of the EU.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.